Comparative efficacy and safety of dupilumab versus newly approved biologics and JAKi in pediatric atopic dermatitis: A systematic review and network meta-analysis

Qiwei Liao, Hanwen Pan, Yixin Guo, Yuxiang Lan, Zhuo Huang and Peiyi Wu

PLOS ONE, 2025, vol. 20, issue 2, 1-17

Abstract: Background: The newly approved biologics and Janus kinase inhibitors (JAKi) for pediatric atopic dermatitis (AD) offer additional options for clinical treatment. However, the efficacy and safety differences compared to the first approved biologic, dupilumab, remain unclear. Therefore, a network meta-analysis was conducted to evaluate these differences and identify potentially superior agents. Methods: This systematic review was PROSPERO-registered (CRD42024583658). Randomized controlled trials involving pediatric patients (

Date: 2025
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0319400 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 19400&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0319400

DOI: 10.1371/journal.pone.0319400

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().